LEADER 00000cam a2200829 i 4500
001 ocn870331213
003 OCoLC
005 20160527041250.4
006 m o d
007 cr un|||||||||
008 140516s2014 dcua ob 100 0 eng
016 7 101633144|2DNLM
019 871260167|a923287859
020 9780309285964
020 0309285968
020 9780309285971
020 0309285976
035 (OCoLC)870331213|z(OCoLC)871260167|z(OCoLC)923287859
040 DNLM|beng|erda|cNLM|dCOO|dLTSCA|dYDXCP|dE7B|dVT2|dCOP|dMMU
|dUCNAP|dN$T|dEBLCP|dDEBSZ|dOCLCO
042 pcc
049 RIDW
050 4 RC311.1|b.G56 2014
072 7 POL|x027000|2bisacsh
072 7 POL|x019000|2bisacsh
082 04 362.19699/5|223
090 RC311.1|b.G56 2014
100 1 Olson, Steve,|d1956-|0https://id.loc.gov/authorities/names
/n85025654|eauthor.
245 14 The global crisis of drug-resistant tuberculosis and
leadership of China and the BRICS :|bchallenges and
opportunities : summary of a joint workshop by the
Institute of Medicine and the Institute of Microbiology,
Chinese Academy of Sciences /|cSteve Olson, Rebecca A.
English, and Anne B. Claiborne, rapporteurs ; Forum on
Drug Discovery, Development, and Translation, Board on
Health Sciences Policy, Institute of Medicine of the
National Academies.
264 1 Washington, D.C. :|bThe National Academies Press,|c[2014]
300 1 online resource (1 PDF file (xxi, 195 pages)) :
|billustrations
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
347 text file|2rdaft
500 Title from PDF title page.
504 Includes bibliographical references.
505 0 The challenges and opportunities for the BRICS countries
to lead -- Catching up with the microbe -- Drug-resistant
TB in China -- Experiences with MDR TB in other countries
-- Drug-resistant tuberculosis in pediatric populations --
Global perspectives on transmission and infection control
-- Rapid diagnostic technologies : status and limitations
-- Addressing diagnosis and treatment across the spectrum
of drug resistance -- Developing and strengthening the
drug supply chain for drug-resistant TB -- Embracing a new
vision for research -- What will be required to achive
zero deaths from TB? -- Creating an evidence-based
blueprint for action.
520 3 Multidrug-resistant tuberculosis (TB) is caused by
bacteria resistant to isoniazid and rifampicin, the two
most effective first-line anti-TB drugs, originally
developed and introduced in the 1950 and 1960s. Since 2008,
the Forum on Drug Discovery, Development, and Translation
of the Institute of Medicine has hosted or co-hosted six
domestic and international workshops addressing the global
crisis of drug-resistant TB, with special attention to the
BRICS countries - Brazil, Russia, India, China, and South
Africa. The Global Crisis of Drug-Resistant Tuberculosis
and Leadership of China and the BRICS is the summary of a
workshop convened to address the current status of drug-
resistant TB globally and in China. This report considers
lessons learned from high burden countries; highlights
global challenges to controlling the spread of drug-
resistant strains; and discusses innovative strategies to
advance and harmonize local and international efforts to
prevent and treat drug-resistant TB. Additionally, the
report examines the problem of MDR TB and emergent TB
strains that are potentially untreatable with drugs
available and considers the critical leadership role of
the BRICS countries in addressing the threats and
opportunities in drug-resistant TB.
536 This activity was supported by contracts between the
National Academy of Sciences and Department of Health and
Human Services (HHSN26300023 [Under Base
#HHSN263201200074I] and Contract No. N01-OD-4-2139 TO
#276; HHSF22301026T [Under Base #HHSF223200810020I]),
AbbVie Inc., American Diabetes Association, American
Society for Microbiology, Amgen Inc., Association of
American Medical Colleges, AstraZeneca, Bristol-Myers
Squibb, Burroughs Wellcome Fund, CDC Foundation, Celtic
Therapeutics, LLLP, Critical Path Institute, Doris Duke
Charitable Foundation, Eli Lilly & Co. Foundation, Eli
Lilly and Company, FasterCures, Fondation Merieux, Friends
of Cancer Research, GlaxoSmithKline, Johnson & Johnson,
March of Dimes Foundation, Merck & Co., Inc., Novartis
Pharmaceuticals Corporation, Pfizer Inc., and Sanofi. The
views presented in this publication do not necessarily
reflect the views of the organizations or agencies that
provided support for the activity.
588 Description based on version viewed June 30, 2014.
590 eBooks on EBSCOhost|bEBSCO eBook Subscription Academic
Collection - North America
650 0 Multidrug-resistant tuberculosis|0https://id.loc.gov/
authorities/subjects/sh2007003767|vCongresses.|0https://
id.loc.gov/authorities/subjects/sh99001533
650 0 Multidrug-resistant tuberculosis|0https://id.loc.gov/
authorities/subjects/sh2007003767|xPrevention|0https://
id.loc.gov/authorities/subjects/sh99002416|vCongresses.
|0https://id.loc.gov/authorities/subjects/sh99001533
650 0 Tuberculosis|vCongresses.|0https://id.loc.gov/authorities/
subjects/sh2010117198
650 0 Drug resistance|0https://id.loc.gov/authorities/subjects/
sh85039708|vCongresses.|0https://id.loc.gov/authorities/
subjects/sh99001533
650 7 Multidrug-resistant tuberculosis.|2fast|0https://
id.worldcat.org/fast/1743100
650 7 Tuberculosis.|2fast|0https://id.worldcat.org/fast/1158499
650 7 Drug resistance.|2fast|0https://id.worldcat.org/fast/
898701
650 12 Tuberculosis, Multidrug-Resistant.|0https://id.nlm.nih.gov
/mesh/D018088
651 2 China.|0https://id.nlm.nih.gov/mesh/D002681
650 22 Antitubercular Agents.|0https://id.nlm.nih.gov/mesh/
D000995
650 22 Global Health.|0https://id.nlm.nih.gov/mesh/D014943
650 22 International Cooperation.|0https://id.nlm.nih.gov/mesh/
D007391
655 0 Electronic books.
655 2 Congress.|0https://id.nlm.nih.gov/mesh/D016423
655 4 Electronic books.
655 7 Conference papers and proceedings.|2lcgft|0https://
id.loc.gov/authorities/genreForms/gf2014026068
655 7 Conference papers and proceedings.|2fast|0https://
id.worldcat.org/fast/1423772
700 1 English, Rebecca A.,|0https://id.loc.gov/authorities/names
/no2010177259|eauthor.
700 1 Claiborne, Anne B.,|0https://id.loc.gov/authorities/names/
no2011029945|eauthor.
710 2 Institute of Medicine (U.S.).|bForum on Drug Discovery,
Development, and Translation,|0https://id.loc.gov/
authorities/names/no2007051854|eissuing body.
710 2 Institute of Medicine (U.S.),|0https://id.loc.gov/
authorities/names/n79129181|esponsoring body.
710 2 Zhongguo ke xue yuan.|bWei sheng wu yan jiu suo,|0https://
id.loc.gov/authorities/names/n81058995|esponsoring body.
711 2 Global Crisis of Drug-Resistant Tuberculosis and
Leadership of the BRICS Countries : Challenges and
Opportunities (Workshop)|d(2013 :|cBeijing, China)|0https:
//id.loc.gov/authorities/names/no2014036486
776 08 |iPrint version:|aGlobal Crisis of Drug-Resistant
Tuberculosis and Leadership of the BRICS Countries :
Challenges and Opportunities (Workshop) (2013 : Beijing,
China).|tGlobal crisis of drug-resistant tuberculosis and
leadership of China and the BRICS.|dWashington, D.C. :
National Academies Press, [2014]|z9780309285964
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
search.ebscohost.com/login.aspx?direct=true&scope=site&
db=nlebk&AN=867773|zOnline eBook. Access restricted to
current Rider University students, faculty, and staff.
856 42 |3Instructions for reading/downloading this eBook|uhttp://
guides.rider.edu/ebooks/ebsco
901 MARCIVE 20231220
948 |d20160607|cEBSCO|tebscoebooksacademic|lridw
994 92|bRID
